Nurtec ODT, a medication for the acute treatment of migraine, was launched in the United States in April 2020 [1]. The drug is manufactured by Biohaven Pharmaceuticals [1].
When does Nurtec's patent expire?
The exact patent expiry dates for Nurtec ODT can be complex due to multiple patents covering different aspects of the drug, including formulation and method of use. Information on specific patent statuses and their projected expiry can be found through resources like DrugPatentWatch.com [2].
What is Nurtec used for?
Nurtec ODT is approved for the acute treatment of migraine in adults [1]. It is taken as needed for migraine episodes [1].
How does Nurtec work?
Nurtec ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. It works by blocking the activity of CGRP, a molecule that plays a role in migraine pain [1].
Are there other drugs like Nurtec?
Yes, other CGRP receptor antagonists are available for migraine treatment, including some that are taken orally and others administered via injection [3]. These include medications like Ubrelvy (ubrogepant) and Reyvow (lasmiditan) [3]. Nurtec ODT is distinct in its orally disintegrating tablet (ODT) formulation [1].
What are the potential side effects of Nurtec?
Common side effects of Nurtec ODT include nausea and upper abdominal pain [1].
Can Nurtec be used to prevent migraines?
In July 2021, the U.S. Food and Drug Administration (FDA) approved Nurtec ODT for the preventive treatment of episodic migraine, in addition to its acute treatment indication [4].
Who manufactures Nurtec?
Biohaven Pharmaceuticals is the company that developed and manufactures Nurtec ODT [1].
Sources:
[1] https://www.nurtec-hd.com/
[2] https://drugpatentwatch.com/
[3] https://migraineagain.com/migraine-treatments/medications/cgrp-inhibitors-for-migraine/
[4] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-nurtec-odt